{
  "id": "nclex_ngn_sa_fes_001",
  "itemType": "standalone",
  "questionType": "priorityAction",
  "question": "Based on the client's electronic health record (EHR), which action should the nurse take FIRST?",
  "case": {
    "patient": {
      "age": "24",
      "gender": "Male",
      "weight": "80 kg",
      "height": "180 cm",
      "allergies": "No known allergies"
    },
    "tabs": [
      {
        "label": "Nurses' Notes",
        "content": [
          {
            "timestamp": "Day 1, 08:00",
            "note": "Client is 12 hours post-op from ORIF right femur. Alert and oriented x3. Reports pain as 3/10 after last dose of morphine. Right lower extremity elevated on two pillows, neurovascular checks intact, pedal pulse +2. Lungs clear to auscultation bilaterally. Client is a temporary agricultural worker and states his family lives in another country."
          },
          {
            "timestamp": "Day 2, 14:00",
            "note": "Called to room for client's restlessness. Client is agitated, confused to place and time. Attempting to pull at IV lines. States, 'I feel like I can't breathe right.' A fine rash of non-blanching, pinpoint red dots is noted across the upper chest, neck, and in the axillae."
          }
        ]
      },
      {
        "label": "Vital Signs",
        "content": [
          {
            "time": "Day 1, 20:00",
            "hr": "92",
            "bp": "128/80",
            "rr": "18",
            "spo2": "97% on room air",
            "temp": "37.2°C (99.0°F)"
          },
          {
            "time": "Day 2, 04:00",
            "hr": "98",
            "bp": "122/76",
            "rr": "20",
            "spo2": "95% on room air",
            "temp": "37.4°C (99.3°F)"
          },
          {
            "time": "Day 2, 12:00",
            "hr": "110",
            "bp": "118/72",
            "rr": "24",
            "spo2": "93% on room air",
            "temp": "37.9°C (100.2°F)"
          },
          {
            "time": "Day 2, 14:00",
            "hr": "128",
            "bp": "105/65",
            "rr": "32",
            "spo2": "89% on room air",
            "temp": "38.1°C (100.6°F)"
          }
        ]
      },
      {
        "label": "Laboratory Results",
        "content": [
          {
            "name": "Complete Blood Count (CBC) - 06:00",
            "results": [
              {
                "test": "WBC",
                "value": "11.5 x 10³/µL",
                "range": "4.5-11.0"
              },
              {
                "test": "Hemoglobin",
                "value": "12.8 g/dL",
                "range": "13.5-17.5"
              },
              {
                "test": "Hematocrit",
                "value": "38%",
                "range": "41-53"
              },
              {
                "test": "Platelets",
                "value": "125,000/mm³",
                "range": "150,000-450,000"
              }
            ]
          },
          {
            "name": "Basic Metabolic Panel (BMP) - 06:00",
            "results": [
              {
                "test": "Sodium",
                "value": "139 mEq/L",
                "range": "135-145"
              },
              {
                "test": "Potassium",
                "value": "4.2 mEq/L",
                "range": "3.5-5.0"
              },
              {
                "test": "BUN",
                "value": "18 mg/dL",
                "range": "7-20"
              },
              {
                "test": "Creatinine",
                "value": "0.9 mg/dL",
                "range": "0.6-1.2"
              }
            ]
          }
        ]
      },
      {
        "label": "Medication Administration Record",
        "content": [
          {
            "medication": "Morphine sulfate 2 mg IV",
            "route": "IV",
            "frequency": "every 2 hours PRN pain",
            "lastGiven": "12:30"
          },
          {
            "medication": "Cefazolin 1 g",
            "route": "IVPB",
            "frequency": "every 8 hours",
            "due": "16:00"
          },
          {
            "medication": "Enoxaparin 40 mg",
            "route": "Subcutaneous",
            "frequency": "Daily",
            "due": "15:00"
          }
        ]
      }
    ]
  },
  "options": [
    {
      "label": "A",
      "content": "Administer the scheduled daily dose of enoxaparin."
    },
    {
      "label": "B",
      "content": "Apply oxygen at 4 L/min via nasal cannula and obtain a full set of vital signs."
    },
    {
      "label": "C",
      "content": "Withhold the scheduled enoxaparin and notify the healthcare provider of the client's new symptoms."
    },
    {
      "label": "D",
      "content": "Request a PRN dose of an anxiolytic medication for the client's agitation."
    }
  ],
  "correctOption": "C",
  "rationale": {
    "correct": "The client is exhibiting signs and symptoms indicative of Fat Embolism Syndrome (FES), a serious complication following long bone fractures. The classic triad of FES includes respiratory distress (tachypnea, hypoxia), neurological changes (confusion, agitation), and a petechial rash. Thrombocytopenia (platelets 125,000/mm³) further supports this diagnosis. In FES, fat globules released from the bone marrow enter the circulation, leading to microvascular occlusion and inflammation, particularly in the lungs and brain. This triggers an inflammatory cascade, causing endothelial damage, increased capillary permeability, and subsequent pulmonary edema and hypoxemia. Neurological symptoms arise from cerebral edema and microemboli. Petechiae result from fat emboli and thrombocytopenia causing capillary rupture. Enoxaparin, an anticoagulant, is contraindicated in this situation due to the increased risk of hemorrhage associated with thrombocytopenia and microvascular damage. Administering enoxaparin could exacerbate bleeding, potentially leading to life-threatening complications such as intracranial hemorrhage. Therefore, the priority action is to withhold the enoxaparin to prevent further harm and immediately notify the healthcare provider to facilitate prompt diagnosis and management of FES, which may include oxygen therapy, fluid management, and potentially corticosteroids.",
    "incorrect": "Options A, B, and D do not address the immediate safety concern related to the potential for hemorrhage and the need for prompt diagnosis and treatment of FES. These options either directly contribute to the risk of harm or delay necessary interventions.",
    "answerBreakdown": [
      {
        "label": "A",
        "content": "Administer the scheduled daily dose of enoxaparin.",
        "isCorrect": false,
        "justification": "Administering enoxaparin, an anticoagulant, is contraindicated in the presence of thrombocytopenia and suspected FES due to the increased risk of hemorrhage. This action could lead to severe complications, including intracranial hemorrhage."
      },
      {
        "label": "B",
        "content": "Apply oxygen at 4 L/min via nasal cannula and obtain a full set of vital signs.",
        "isCorrect": false,
        "justification": "While oxygen administration is appropriate for the client's hypoxia, it does not address the immediate risk of administering a contraindicated medication. Addressing the medication safety issue takes priority. Obtaining vital signs is important but secondary to preventing harm."
      },
      {
        "label": "C",
        "content": "Withhold the scheduled enoxaparin and notify the healthcare provider of the client's new symptoms.",
        "isCorrect": true,
        "justification": "This is the priority action. Withholding the enoxaparin prevents potential harm from hemorrhage. Notifying the healthcare provider ensures prompt evaluation and management of the suspected FES. This action addresses both the immediate safety concern and the need for further medical intervention."
      },
      {
        "label": "D",
        "content": "Request a PRN dose of an anxiolytic medication for the client's agitation.",
        "isCorrect": false,
        "justification": "The client's agitation is likely due to cerebral hypoxia secondary to FES, not anxiety. Administering an anxiolytic would mask the underlying neurological deterioration and delay appropriate treatment for FES."
      }
    ]
  },
  "pedagogy": {
    "bloomLevel": "Analyzing",
    "cjmmStep": "Recognize Cues, Analyze Cues, Prioritize Hypotheses, Take Actions",
    "nclexCategory": "Pharmacological and Parenteral Therapies",
    "difficulty": "Hard",
    "topicTags": [
      "Fat Embolism Syndrome",
      "Postoperative Complications",
      "Medication Safety",
      "Anticoagulants",
      "Safety and Infection Control",
      "Critical Thinking"
    ]
  },
  "scenario": {
    "sbar": {
      "situation": "24-year-old male, 24 hours post-op ORIF right femur, receiving scheduled medications.",
      "background": "At 0800, client alert and oriented x3, pain 3/10 after morphine. Neurovascular checks intact, lungs clear. Temporary agricultural worker.",
      "assessment": "At 1400, client restless, agitated, confused to place/time, pulling at IV lines, reports dyspnea. Non-blanching petechial rash on upper chest, neck, axillae. HR 128, BP 105/65, RR 32, SpO2 89% on room air, Temp 38.1°C. Platelets 125,000/mm3.",
      "recommendation": "Recommend withholding enoxaparin due at 1500 and notifying the provider immediately due to suspected Fat Embolism Syndrome (FES)."
    }
  },
  "clinicalPearl": "Remember the classic triad of Fat Embolism Syndrome (FES): respiratory distress, neurological changes, and petechial rash. Thrombocytopenia is often present. Early recognition and intervention are critical to prevent severe complications.",
  "sentinelStatus": "healed_v2026_v8"
}